Stable Incidence and Poor Survival for HIV-Related Burkitt Lymphoma Among the US Veteran Population During the Antiretroviral Era

Background: Despite advances in diagnosis and treatment of both HIV and Burkitt lymphoma (BL), persons living with HIV remain at high risk for BL. We conducted this study to evaluate if there have been any changes in the risk of or survival after BL diagnosis among persons living with HIV during the antiretroviral era. Setting: Veterans living with HIV (VLWH) and age-matched HIV-negative controls receiving care between 1999 and 2016 were retrospectively identified using Veterans Health Administration electronic medical records. Methods: We identified BL diagnoses through Veterans Health Administration Cancer Registry review and International Classification of Diseases, Ninth/Tenth Revisions, codes, and we extracted demographic, lifestyle, and clinical variables from electronic medical record. We estimated hazard ratios (HR) and 95% confidence intervals (CIs) for BL risk and survival using Cox proportional models. Results: We identified 45,299 VLWH. Eighty-four developed BL (incidence rate = 21.2 per 100,000 person years; CI: 17.1 to 26.3). Median CD4 count at BL diagnosis was 238 cells per milliliter (SD: 324.74) and increased over time. Survival was truncated in VLWH with BL (P
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Epidemiology Source Type: research

Related Links:

renti The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B cell lymphoma, and Waldenstrom's macroglobulinemia. This finding has resulted in the development of numerous drugs that target this pathway, including various inhibitors of the kinases BTK, PI3K, and SYK. Several of these drugs have been approved in recent years for clinical use, resulting in a profound change in the way these disease...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
(NIH/National Cancer Institute) In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Contributors : Kim Doyeun ; Kim SunghoonSeries Type : Expression profiling by arrayOrganism : Mus musculusAIMP2-DX2 is known as a cancer-associated splicing variant of tumor suppressor, AIMP2, lacking exon 2 (shortly DX2 herein). However, it is not known whether its expression alone can drive tumorigenesis. Here we show that DX2 can induce the expansion of germinal center (GC) origin B lymphocytes and their infiltration into multi-organs in mouse model. In doxycycline-dependent inducible transgenic mice, monoclonal expansion of B cells with malignant transformation was developed in two out of seven cases. Induction of DX2 ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
Publication date: Available online 18 May 2020Source: Cancer GeneticsAuthor(s): Beata Grygalewicz, Renata Woroniecka, Grzegorz Rymkiewicz, Jolanta Rygier, Natalia Malawska, Katarzyna Blachnio, Zbigniew Bystydzienski, Anita Borysiuk, Beata Nowakowska, Barbara Pienkowska-Grela
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
ConclusionAutologous anti-CD19, anti-CD22, and anti-CD20 CAR-T cell therapies targeting multiple tumor antigens could be an innovative and sound treatment for children with r/r BL, provided that they are closely monitored during treatment.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Beata Grygalewicz: Conceptualization, Investigation, Methodology, Writing - Original Draft, Renata Woroniecka: Formal analysis, Investigation, Writing - Review&Editing, Grzegorz Rymkiewicz: Formal analysis, Writing - Review&Editing, Jolanta Rygier: Investigation, Natalia Malawska: Investigation, Zbigniew Bystydzienski: Investigation, Katarzyna Blachnio: Investigation, Anita Borusiuk: Investigation, Beata Nowakowska: Resources, Barbara Pienkowska-Grela: Supervision, Writing - Review&Editing.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Conclusion: Our findings suggested that combination therapy with ATV and 131I-RTX is a promising strategy for enhancing the potency of 131I-RTX therapy in poorly responding patients and those with radio-resistance.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Stenodactylin, a highly toxic type 2 ribosome-inactivating protein purified from the caudex of Adenia stenodactyla Harms, is a potential anticancer drug candidate. Previous studies demonstrated that stenodactylin induces apoptosis and necroptosis in treated cells, involving the production of reactive oxygen species. We analyzed the effect of stenodactylin on Raji and Ramos (Human Burkitt’s lymphoma cells) and MOLM-13 (acute myeloid leukemia cells). Moreover, we focused on the early events in MOLM-13 cells that characterize the cellular response to the toxin by whole-genome microarray analysis of gene expression. Trea...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The Tumor Microenviroment (TME) is a complex milieu that is increasingly recognized as a key factor in multiple stages of disease progression and responses to therapy as well as escape from immune surveillance...
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Our study included 477 Burkitt Lymphoma (BL) patients with gastrointestinal involvement extracted from the SEER database between 2004 and 2015, 112 (23.5%) with the stomach and 365 (76.5%) with the intestine. We demonstrated that BL patients with gastric involvement had an inferior prognosis compared to those with intestinal involvement (5 ‐year OS 37.8% vs. 70.2%). In subgroup analysis, gastric BL patients had a consistently worse OS than intestinal patients regardless of gender, clinical stage and year of diagnosis. AbstractDue to limited information reported on the clinical characteristics and outcomes of Burkitt lymp...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Burkitt Lymphoma | Cancer | Cancer & Oncology | Electronic Medical Records (EMR) | Epidemiology | Infectious Diseases | Lymphoma | Study